Nuvectis Pharma, Inc. Financials

NVCT

Source SEC Filings (10-K/10-Q) Updated Feb 11, 2026 Currency USD FYE February

Financial Health Signals

Piotroski F-Score Neutral

4/9

Nuvectis Pharma, Inc. passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Mixed

0.61x

For every $1 of reported earnings, Nuvectis Pharma, Inc. generates $0.61 in operating cash flow ($16K OCF vs $26K net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

This page shows Nuvectis Pharma, Inc. (NVCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

N/A

Free Cash Flow

N/A

Net Income

$26K

YoY+100.1%

Nuvectis Pharma, Inc. reported $26K in net income in fiscal year 2025. This represents an increase of 100.1% from the prior year.

EPS (Diluted)

$1.32

YoY+218.9%

Nuvectis Pharma, Inc. earned $1.32 per diluted share (EPS) in fiscal year 2025. This represents an increase of 218.9% from the prior year.

Cash & Debt

$32K

YoY-99.8%

Nuvectis Pharma, Inc. held $32K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.00

Nuvectis Pharma, Inc. paid $0.00 per share in dividends in fiscal year 2025.

Shares Outstanding

26M

YoY+35.9%

Nuvectis Pharma, Inc. had 26M shares outstanding in fiscal year 2025. This represents an increase of 35.9% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$18K

YoY-99.9%

Nuvectis Pharma, Inc. invested $18K in research and development in fiscal year 2025. This represents a decrease of 99.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

NVCT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$18K-99.9%	$12.9M-16.0%	$15.4M+16.3%	$13.2M+38.6%	$9.5M
SG&A Expenses	$9K-99.9%	$6.9M-7.8%	$7.5M+25.1%	$6.0M+79.4%	$3.3M
Operating Income	$28K+100.1%	-$19.8M+13.3%	-$22.9M-19.0%	-$19.2M-49.2%	-$12.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A
Net Income	$26K+100.1%	-$19.0M+14.6%	-$22.3M-16.6%	-$19.1M-48.1%	-$12.9M
EPS (Diluted)	$1.32+218.9%	$-1.11+22.4%	$-1.43+5.3%	$-1.51	$-3.02

Metric	Q4'25	Q3'25	Q4'24	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$5.8M	N/A	$2.8M	N/A	$4.5M	N/A	$4.5M
SG&A Expenses	N/A	$2.0M	N/A	$1.5M	N/A	$1.7M	N/A	$1.4M
Operating Income	N/A	-$7.8M	N/A	-$4.4M	N/A	-$6.2M	N/A	-$5.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$7.5M	N/A	-$4.2M	N/A	-$5.9M	N/A	-$5.9M
EPS (Diluted)	N/A	$-0.44	N/A	$-0.24	N/A	$-0.37	N/A	$-0.42

NVCT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	$32K-99.8%	$18.6M-3.0%	$19.2M-6.0%	$20.4M+206.5%	$6.7M
Current Assets	$32K-99.8%	$18.6M-3.0%	$19.2M-6.0%	$20.4M+249.8%	$5.8M
Cash & Equivalents	$32K-99.8%	$18.5M-3.1%	$19.1M-4.3%	$20.0M+248.2%	$5.7M
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$32K-99.6%	$8.9M+27.3%	$7.0M+12.9%	$6.2M-65.0%	$17.7M
Current Liabilities	$13K-99.9%	$8.9M+27.3%	$7.0M+12.9%	$6.2M+155.7%	$2.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	$0-100.0%	$9.7M-20.4%	$12.2M-14.2%	$14.2M+229.2%	-$11.0M
Retained Earnings	$100K+100.1%	-$73.2M-35.0%	-$54.2M-69.6%	-$32.0M-147.9%	-$12.9M

Metric	Q4'25	Q3'25	Q4'24	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22
Total Assets	$31.7M-10.9%	$35.6M+91.3%	$18.6M+7.5%	$17.3M-9.8%	$19.2M-13.8%	$22.3M+9.1%	$20.4M-17.9%	$24.9M
Current Assets	$31.7M-10.9%	$35.6M+91.3%	$18.6M+7.5%	$17.3M-9.8%	$19.2M-13.8%	$22.3M+9.1%	$20.4M-17.9%	$24.9M
Cash & Equivalents	$31.6M-10.7%	$35.4M+91.2%	$18.5M+7.9%	$17.2M-10.2%	$19.1M-13.3%	$22.1M+10.3%	$20.0M-15.4%	$23.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.3M+14.8%	$11.6M+30.2%	$8.9M+40.8%	$6.3M-9.6%	$7.0M+25.3%	$5.6M-9.9%	$6.2M+37.7%	$4.5M
Current Liabilities	$13.3M+14.8%	$11.6M+30.2%	$8.9M+40.8%	$6.3M-9.6%	$7.0M+25.3%	$5.6M-9.9%	$6.2M+37.7%	$4.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$18.4M-23.3%	$24.0M+147.2%	$9.7M-11.6%	$11.0M-9.9%	$12.2M-26.9%	$16.7M+17.4%	$14.2M-30.2%	$20.4M
Retained Earnings	-$99.7M-7.9%	-$92.4M-26.1%	-$73.2M-9.3%	-$67.0M-23.5%	-$54.2M-13.9%	-$47.6M-48.9%	-$32.0M-26.5%	-$25.3M

NVCT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	$16K+100.1%	-$12.2M+23.2%	-$16.0M-17.7%	-$13.6M-42.7%	-$9.5M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$0	$0	$0	N/A
Financing Cash Flow	$29K-99.8%	$11.7M-22.8%	$15.1M-45.7%	$27.8M+82.4%	$15.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q4'24	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22
Operating Cash Flow	-$4.0M+11.6%	-$4.5M-82.3%	-$2.5M-2.5%	-$2.4M+37.6%	-$3.9M-18.7%	-$3.2M+7.7%	-$3.5M+20.5%	-$4.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$0	N/A	$0	N/A	N/A	N/A	N/A
Financing Cash Flow	$166K-98.7%	$13.1M+243.2%	$3.8M+162.8%	$1.5M+58.9%	$917K+30.4%	$703K+636.6%	-$131K-100.9%	$14.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NVCT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A
Return on Assets	83.4%+185.5pp	-102.1%+13.9pp	-116.0%-22.5pp	-93.5%+100.1pp	-193.6%
Current Ratio	2.38+0.3	2.09-0.7	2.75-0.6	3.30+0.9	2.41
Debt-to-Equity	0.72-0.2	0.92+0.3	0.57+0.1	0.44+2.0	-1.60
FCF Margin	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q4'24	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-21.0%	N/A	-24.0%	N/A	-26.4%	N/A	-23.6%
Current Ratio	2.38-0.7	3.07+1.0	2.09-0.6	2.740.0	2.75-1.2	3.99+0.7	3.30-2.2	5.54
Debt-to-Equity	0.72+0.2	0.48-0.4	0.92+0.3	0.570.0	0.57+0.2	0.33-0.1	0.44+0.2	0.22
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative ($0), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Ventyx Biosciences, Inc. VTYX

$1.0B

Aardvark Therapeutics AARD

$263.5M

Instil Bio, Inc. TIL

$54.2M

Sangamo Therapeutics Inc SGMO

$143.8M

Actuate Therapeutics Inc ACTU

$100.6M

Frequently Asked Questions

Is Nuvectis Pharma, Inc. profitable?

Yes, Nuvectis Pharma, Inc. (NVCT) reported a net income of $26K in fiscal year 2025.

What is Nuvectis Pharma, Inc.'s earnings per share (EPS)?

Nuvectis Pharma, Inc. (NVCT) reported diluted earnings per share of $1.32 for fiscal year 2025. This represents a 218.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Nuvectis Pharma, Inc.'s operating cash flow?

Nuvectis Pharma, Inc. (NVCT) generated $16K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Nuvectis Pharma, Inc.'s total assets?

Nuvectis Pharma, Inc. (NVCT) had $32K in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Nuvectis Pharma, Inc. spend on research and development?

Nuvectis Pharma, Inc. (NVCT) invested $18K in research and development during fiscal year 2025.

How many shares does Nuvectis Pharma, Inc. have outstanding?

Nuvectis Pharma, Inc. (NVCT) had 26M shares outstanding as of fiscal year 2025.

What is Nuvectis Pharma, Inc.'s current ratio?

Nuvectis Pharma, Inc. (NVCT) had a current ratio of 2.38 as of fiscal year 2025, which is generally considered healthy.

What is Nuvectis Pharma, Inc.'s debt-to-equity ratio?

Nuvectis Pharma, Inc. (NVCT) had a debt-to-equity ratio of 0.72 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Nuvectis Pharma, Inc.'s return on assets (ROA)?

Nuvectis Pharma, Inc. (NVCT) had a return on assets of 83.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is Nuvectis Pharma, Inc.'s debt-to-equity ratio negative or unusual?

Nuvectis Pharma, Inc. (NVCT) has negative shareholder equity of $0 as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Nuvectis Pharma, Inc.'s Piotroski F-Score?

Nuvectis Pharma, Inc. (NVCT) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Nuvectis Pharma, Inc.'s earnings high quality?

Nuvectis Pharma, Inc. (NVCT) has an earnings quality ratio of 0.61x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.